3rd NGN-PET meeting

NGN-PET Project held its 3rd face-to-face meeting in Bresso, at AXXAM’s headquarters. Representatives of all the partners and the IMI Officer, Colm Carroll, joint the meeting. Like in previous editions, the meeting was a excellent opportunity to share and discuss the results we had obtained so far, and to agree on next steps. The NGN-PET project has accomplished with the…

Axxam coordinates European research project on chronic pain for innovative medicines

Axxam coordinates European research project on chronic pain for innovative medicines

Axxam is proud to announce its participation to the NGN-PET project, that will provide a translational platform of rodent and human neuropathic pain models for the identification and validation of new targets and biomarkers, and suitable for the discovery of new drugs. The project investigates neuron-glia interactions for the identification of novel therapeutic approaches, and for the development of innovative…

New Innovative Medicine Initiative funding award

Professor Stephen McMahon and Dr Franziska Denk from the Wolfson Centre for Age-Related Diseases have been awarded EUR 450,000, as part of a new European research consortium funded by the Innovative Medicine Initiative (IMI2). The consortium, named NGN-PET, brings together partners from industry and academia and has a total budget of 3.3 million Euros over three years. It aims to…

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain

The NGN-PET consortium aims to explore neuron-glial interactions in subtypes of neuropathic pain which are induced by chemotherapy or trauma, and to develop human-predictive test systems that can be implemented in the drug discovery process. These cellular systems will use preclinical tissues and human iPSC-derived neuron-glia co-culturesin novel high-throughput screening platfor to identify novel more efficacious treatments for neuropathic pain…

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain

NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. ESTEVE, along with five other partners, is part of this project for the development of novel, more efficacious treatments for chronic pain of neuropathic origin Neuropathic pain affects…

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain

Esteve co-leads international consortium for the development of more efficacious therapies for neuropathic pain

Esteve at the Barcelona Science Park co-leads the NGN-PET consortium, that unites the expertise and knowledge of industry partners from the European Federation of Pharmaceutical Industries and Associations (EFPIA), small and medium-sized enterprises (SMEs) and academia for the development of novel, more efficacious treatments for chronic pain of neuropathic origin. NGN-PET is a project launched in the framework of the Innovative Medicine Initiative (IMI), the largest…

NGN-PET Project Launch

NGN-PET Project Launch

Launch of the project: Modelling neuron-glia networks into a drug discovery platform for pain efficacious treatments (NGN-PET) The new research project NGN-PET was launched in the framework of the Innovative Medicine Initiative (IMI), the largest public-private partnership (PPP) for health research worldwide co-funded by the EU and the European pharmaceutical industry. The NGN-PET consortium unites the expertise and knowledge of…